Scholar Rock stock falls after FDA issues response letter for SMA drug
NegativeFinancial Markets

Scholar Rock's stock has taken a hit following the FDA's recent response letter regarding its SMA drug. This news is significant as it raises concerns about the drug's approval timeline and the company's future prospects in the competitive pharmaceutical market. Investors are closely watching how this will impact Scholar Rock's operations and its ability to bring innovative treatments to patients.
— Curated by the World Pulse Now AI Editorial System